Eosinophilic disorders

Eosinophilic disorders happen when there is a problem with the eosinophils, a type of white blood cell. Sometimes they move outside the blood stream to other organs.

Programs + Services


Allergy

The Allergy Division at Tufts Medical Center provides diagnosis and care for patients who have a wide range of allergies and other related disorders.
More information about programs and services


Eosinophilic Esophagitis Program

The doctors in the Eosinophilic Esophagitis (EoE) Program at Tufts Medical Center provide a range of treatment options for EoE in our downtown Boston location.
More information about programs and services

Doctors + Care Team

John L. Ohman, Jr., MD

John L. Ohman, Jr., MD

Accepting New Patients

Title(s): Chief, Division of Allergy; Professor, Tufts University School of Medicine
Department(s): Medicine, Rheumatology, Allergy and Immunology
Appt. Phone: 617-636-5333
Fax #: 617-636-4843

Asthma, hay fever, chronic sinusitis, food allergy, adverse drug reactions, insect sting allergy, occupational allergy/ respiratory disease, atopic eczema, hives/urticaria, adult immunodeficiency, skin testing, pulmonary function testing, allergen challenge

View Full Profile for John L. Ohman, Jr., MD

John Leung, MD

John Leung, MD

Accepting New Patients

Title(s): Director, Center for Food Related Diseases at Tufts Medical Center; Co-Director, Food Allergy Center at Floating Hospital for Children; Allergist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Pediatric Allergy, Gastroenterology, Pediatric Gastroenterology
Appt. Phone: 617-636-5883 (Gastroenterology)
Fax #: 617-636-9292

Allergic rhinitis (seasonal allergy), anaphylaxis, angioedema, asthma, celiac disease, chronic urticarial (hives), drug allergies, eczema, eosinophilic esophagitis/eosinophilic gastrointestinal disorders, food allergy (e.g. peanuts, cow milk, soy, etc.), food intolerance (lactose, fructose, fructan), food protein-induced enterocolitis syndrome (FPIES), immunodeficiency, oral allergy syndrome, pruritus, sinusitis, stinging insect allergy, wheat hypersensitivity

View Full Profile for John Leung, MD

Research + Clinical Trials


A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients with Eosinophilic Gastritis with or without Eosinophilic Gastroenteritis

This study is being conducted to test the efficacy and safety of AK002 in patients with Eosinophilic Gastritis with or without Eosinophilic Gastroenteritis and requires nine study visits over the course of 24 weeks. Participants will receive study drug or placebo via infusion during four of these visits. 
More information about research and clinical trials


FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo- controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis 

FLUTE is a randomized, double-blind, placebo-controlled dose-ranging study of 4 total dailydoses of APT-1011 versus placebo in 100 adult subjects (at least 18 years of age) diagnosed with EoE. During the single-blind run-in/baseline symptom assessment, the subjects will receive placebo 30 minutes after breakfast and HS (at bedtime). APT-1011 will be administered in 4 doses: Placebo 30 minutes after breakfast and 1.5 mg HS (at bedtime), 1.5 mg BID (30 minutes after breakfast and at bedtime; total daily dose of 3 mg), 3 mg HS (at bedtime), and 3 mg BID (30 minutes after breakfast and at bedtime; total daily dose of 6 mg), compared with matching placebo administered 30 minutes after breakfast and HS (at bedtime). The randomization scheme is discussed in Section 4.1.5.2. Efficacy (histological response), safety, and PK of APT-1011 will be examined. 
FLUTE will enroll around 100 adult (at least 18 years of age) subjects (see Section 8.1 for a discussion of the potential number of subjects to participate in each part). 
FLUTE is planned to be performed at approximately 60 active sites in North America (US and Canada) and Western Europe (Belgium, Germany and Spain). The study will be conducted in several parts (Screening, 4-week single-blind placebo run-in and Baseline Symptom Assessment, and 2 treatment parts [Part 1 and Part 21) with a Follow-up Visit to occur 2 weeks after the final dose of study drug. Subjects who enter and complete FLUTE will be in the study for up to 62 weeks until the last subject completes Week 28. 
More information about research and clinical trials